hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06305624 id: 2024-0130 id: 1R01DA047279-01 type: NIH link: https://reporter.nih.gov/quickSearch/1R01DA047279-01 id: A532000 type: OTHER domain: UW Madison id: Protocol Version 2/21/2024 type: OTHER domain: UW Madison briefTitle: Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease acronym: IMPACT-ALD overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2027-10 date: 2027-10 date: 2024-03-12 date: 2024-03-15 name: University of Wisconsin, Madison class: OTHER name: National Institute on Drug Abuse (NIDA) briefSummary: This protocol describes a randomized controlled trial testing the effectiveness and implementability of the CHESS Health Connections smartphone application among patients with alcohol-associated liver disease (ALD) at two medical centers in Michigan and Wisconsin, in two types of clinics: general hepatology and multidisciplinary that offers care for advanced ALD alongside co-located, integrated mental health and substance abuse treatment. The long-term goal of this and future work is to prevent disease progression and promote healthy behaviors by improving the rate of abstinence among patients with ALD earlier in the course of their disease. 298 participants will be enrolled and can expect to be on study for up to 6 months. conditions: Alcohol Use Disorder conditions: Alcohol-related Liver Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized, controlled, Type 1 hybrid implementation-effectiveness trial. primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 298 type: ESTIMATED name: Connections App measure: Days of Alcohol Abstinence in ALD Participants measure: Number of Standard Drinks Consumed in ALD Participants measure: Change in Patient Health Questionnaire (PHQ-8) Score measure: Change in PROMIS Global Health Score measure: Change in Generalized Anxiety Disorder (GAD-7) Score measure: Change in Insomnia Severity Index (ISI) Score measure: Change in Pain Interference (PEG) Score measure: Change in Drinking Motivations Questionnaire - Adult (DMQ-A) Score measure: Change in CHESS Bonding Scale Score measure: Change in Drug-Taking Confidence Questionnaire (DTCQ-8A) Score measure: Change in Treatment Self-Regulation Questionnaire (TSRQ) Score sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UM General Hepatology Clinic city: Ann Arbor state: Michigan zip: 48109 country: United States lat: 42.27756 lon: -83.74088 facility: UM Multidisciplinary ALD Clinic city: Ann Arbor state: Michigan zip: 48109 country: United States lat: 42.27756 lon: -83.74088 facility: UW General Hepatology Clinic city: Madison state: Wisconsin zip: 53705 country: United States lat: 43.07305 lon: -89.40123 facility: UW Multidisciplinary ALD Clinic city: Madison state: Wisconsin zip: 53705 country: United States lat: 43.07305 lon: -89.40123 hasResults: False
nctId: NCT06305598 id: I-3298823 id: NCI-2024-01390 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: I-3298823 type: OTHER domain: Roswell Park Cancer Institute briefTitle: Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer overallStatus: RECRUITING date: 2024-06-01 date: 2026-04-01 date: 2027-04-01 date: 2024-03-12 date: 2024-04-25 name: Roswell Park Cancer Institute class: OTHER briefSummary: This phase I trial tests the change in androgen receptor sensitivity, side effects and effectiveness of bipolar androgen therapy, using testosterone, in patients with castration resistant prostate cancer that has spread to other places is the body (metastatic). Bipolar androgen therapy is the regulation of testosterone between castration levels (lower than what would be normally present) and supraphysiological levels (amounts greater than normally found in the body). This may suppress cancer cell growth, which reduces prostate-specific antigen (PSA) levels and may delay cancer progression. conditions: Castration-Resistant Prostate Carcinoma conditions: Metastatic Prostate Carcinoma conditions: Stage IVB Prostate Cancer AJCC v8 studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 14 type: ESTIMATED name: Biopsy name: Bone Scan name: Computed Tomography name: Leuprolide Acetate name: Magnetic Resonance Imaging name: Survey Administration name: Testosterone Cypionate measure: Androgen receptor (AR) activity measure: Incidence of adverse events measure: Incidence of serious adverse events measure: Prostate specific antigen (PSA) 50 measure: Measurable disease response measure: Progression free survival measure: Overall survival measure: Assess Quality of life measure: Assess Quality of Life measure: Assess Fatigue measure: Assess change in Fatigue sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Roswell Park Cancer Institute status: RECRUITING city: Buffalo state: New York zip: 14263 country: United States name: Gurkamal S. Chatta role: CONTACT phone: 716-845-3117 email: Gurkamal.Chatta@RoswellPark.org name: Gurkamal S. Chatta role: PRINCIPAL_INVESTIGATOR lat: 42.88645 lon: -78.87837 hasResults: False
nctId: NCT06305585 id: IRB# 23-214 briefTitle: Can a Novel Manual Therapy Technique Help Relieve Stress? Assessing Effects of Primal Reflex Release on the Body's Stress Response overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-03 date: 2025-03 date: 2024-03-12 date: 2024-03-12 name: University of Idaho class: OTHER name: CJ Brush name: Jayme Baker name: Sydney Leverett briefSummary: Stress, when left unmanaged, can have detrimental effects on both physical and mental health, contributing to conditions such as high blood pressure, anxiety, and even cardiovascular disease. Effective stress management therapies may help maintain overall well-being and reduce the risk of long-term health complications. The Primal Reflex Release Technique (PRRT) is a novel manual therapy that may reduce markers related to stress such as heart rate variability (HRV) and patient-reported outcomes (PROs). Therefore, the purpose of this study is to elucidate the potential for PRRT to improve HRV and PROs. conditions: Psychological Stress studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Primal Reflex Release Technique (PRRT) measure: ECG Data measure: ICG Data measure: Depression Anxiety Stress Scale-21 (DASS-21) - Depression measure: Depression Anxiety Stress Scale-21 (DASS-21) - Anxiety measure: Depression Anxiety Stress Scale-21 (DASS-21) - Stress measure: Simple Physical Activity Questionnaire (SIMPAQ) measure: Self Assessment Manikin (SAM) - Valence measure: Self Assessment Manikin (SAM) - Arousal sex: ALL minimumAge: 18 Years maximumAge: 64 Years stdAges: ADULT facility: ISMaRT Clinic city: Moscow state: Idaho zip: 83843 country: United States name: Jayme Baker, DPT role: CONTACT phone: 208-885-1055 email: jaymeb@uidaho.edu lat: 46.73239 lon: -117.00017 hasResults: False
nctId: NCT06305572 id: H-1903-013-1014 briefTitle: Diagnostic Accuracy of Quantitative Flow Ratio overallStatus: COMPLETED date: 2019-07-30 date: 2023-03-25 date: 2023-09-26 date: 2024-03-12 date: 2024-03-12 name: Seoul National University Hospital class: OTHER name: Inje University Ilsan Paik Hospital name: Keimyung University Dongsan Medical Center name: Ulsan Medical Center name: Bucheon Sejong Hospital name: Chosun University Hospital name: Severance Hospital name: Ulsan University Hospital name: Uijeongbu Eulji Medical Center briefSummary: The aim of this study was to investigate the accuracy of quantitative flow ratio (QFR) for predicting fractional flow reserve (FFR) ≤0.80 in an independent core laboratory. conditions: Coronary Artery Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 280 type: ACTUAL name: QFR measure: Diagnostic accuracy of QFR measure: Sensitivity of QFR measure: Specificity of QFR measure: Correlation sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Seoul National University Hospital city: Seoul zip: 03080 country: Korea, Republic of lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06305559 id: OBEZ-302 briefTitle: A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque acronym: REMBRANDT overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-12 date: 2027-03 date: 2024-03-12 date: 2024-03-12 name: NewAmsterdam Pharma class: INDUSTRY briefSummary: This placebo-controlled, double-blind, randomized, Phase 3 study is being conducted in adult participants with high-risk atherosclerotic cardiovascular disease (ASCVD) who are not adequately controlled by their maximally tolerated lipid-modifying therapy, to assess the impact of the obicetrapib 10 mg + ezetimibe 10 mg FDC daily on coronary plaque and inflammation characteristics, evaluated using cardiovascular computed tomography angiography (CCTA). conditions: Lipidemia conditions: Coronary Artery Disease conditions: Plaque, Atherosclerotic studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE maskingDescription: Double blind set-up; post randomization LDL values are not provided to sites (alert triggers are programmed for urgent follow-up) whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 300 type: ESTIMATED name: obicetrapib 10 mg + ezetimibe 10 mg FDC daily name: Placebo measure: • To evaluate the effect of obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC) daily on total non-calcified coronary atherosclerotic plaque volume (NCPV) at 18 months. measure: Absolute change from baseline to 18 months in total NCPV in all major epicardial coronary arteries, as measured by CCTA, in participants treated with obicetrapib 10 mg + ezetimibe 10 mg FDC therapy compared with placebo. measure: Percent change from baseline to 18 months in LDL-C in participants treated with obicetrapib 10 mg + ezetimibe 10 mg FDC therapy compared to placebo. measure: Percent change from baseline to 18 months in non-calcified coronary atherosclerotic plaque volume in the most diseased coronary segment (NCPVMD), as measured by CCTA, in participants treated with FDC therapy vs placebo measure: Absolute change from baseline to 18 months in NCPVMD, as measured by CCTA, in participants treated with obicetrapib 10 mg + ezetimibe 10 mg FDC therapy compared with placebo. measure: Change in perivascular fat attenuation index (FAI), FAI score and its age- and gender specific centile in the principal epicardial coronary arteries as measured by CCTA in participants treated with FDC therapy compared with placebo. sex: ALL minimumAge: 45 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06305546 id: 2911 briefTitle: Comparisons Of Different Antiplaque Agents On Gingivitis In Orthodontic Patients overallStatus: COMPLETED date: 2023-04-01 date: 2023-10-31 date: 2023-10-31 date: 2024-03-12 date: 2024-03-13 name: Anam Sattar class: OTHER briefSummary: Fixed orthodontic treatment affects the periodontium by allowing plaque accumulation on teeth if the oral ecosystem is unfavorable which initially causes gingivitis to progress into periodontitis, and later enamel demineralization occurs. Yáñez-Vico et al observed that regular modifications per checkups were painful and unpleasant for the patient thus the patients undergoing fixed orthodontic treatments compromised their oral hygiene. This creates plaque retention sites which can lead to developing white spot lesions, caries, and periodontitis conditions: Gingivitis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: TRIPLE maskingDescription: The trial was a double blinded (patients and investigators). We were helped from a member of our department who is not a part of the study, to transfer the gels from commercial tubes to blank containers. The randomization codes remained unknown until data analysis was completed. Randomization was done by computer-generated software. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 80 type: ACTUAL name: Chlorhexidine Gluconate name: Metronidazole name: combination gel (chlorhexidine and metronidazole) name: Placebo measure: gingival index measure: bleeding index measure: orthodontic plaque index sex: ALL minimumAge: 16 Years maximumAge: 35 Years stdAges: CHILD stdAges: ADULT facility: Dow University of Health Sciences city: Karachi state: Sindh country: Pakistan lat: 24.8608 lon: 67.0104 hasResults: False
nctId: NCT06305533 id: 854623 briefTitle: Efficacy of Photodynamic Therapy and LASER Disinfection in Periodontal Therapy for Treatment of Periodontitis overallStatus: RECRUITING date: 2024-03-01 date: 2024-09 date: 2024-10 date: 2024-03-12 date: 2024-03-12 name: University of Baghdad class: OTHER briefSummary: The goal of this clinical trial is to Investigate the clinical and microbiological efficacies of Laser disinfection and ICG-mediated aPDT as adjunct to RSD for patients with periodontitis. The main question it aims to answer is:
All the patients will be instructed to attend again after 7 days. One week later, sites randomly allocated to control (Ctrl) group and test groups which will receive, in addition to RSD, either aPDT or periodontal pocket disinfection (Biolase). For all groups, sites with initial PPD 4-6 mm will be treated with RSD using area specific (Graecy) curettes. conditions: Periodontitis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This study is 3 arm, split-mouth, double blinded, randomized clinical trial. The first group will receive RSD only, the second group will be treated with RSD + aPDT with ICG as a PS, and the last group will receive RSD + Laser disinfection. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Sites will randomly be assigned to test or control groups according to a computer-generated list. Allocation concealment will be assured by opaque, sealed envelopes prepared and sequentially numbered by a person not otherwise involved in the study. The person responsible for delivering treatment will be aware about allocation of the groups, while the assessor will be blinded. whoMasked: OUTCOMES_ASSESSOR count: 18 type: ESTIMATED name: LASER disinfection name: Photodynamic therapy name: Root surface debridement measure: Probing Pocket Depth (PPD) measure: Bleeding on probing (BOP) measure: Plaque index (PI) measure: Clinical attachment loss (CAL) measure: Change in bacterial load of F. nucleatum and Fretibacterium fastidiosum sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: College of Dentistry, University of Baghdad status: RECRUITING city: Baghdad zip: 10047 country: Iraq role: CONTACT phone: +964 14169394 email: master@codental.uobaghdad.edu.iq lat: 33.34058 lon: 44.40088 hasResults: False
nctId: NCT06305520 id: BPLUS-NASAL-02 id: CRIS NO. : KCT0008113 type: REGISTRY domain: The Clinical Research Information Service (CRIS) in KOREA briefTitle: Medical Device Pivotal Study to Injection With SkinPlus-HYAL Implant Lidocaine vs RESTYLANE Lidocaine in of Nasolabial Folds acronym: BPLUS-02 overallStatus: ENROLLING_BY_INVITATION date: 2023-03-10 date: 2024-09-30 date: 2024-10-31 date: 2024-03-12 date: 2024-03-15 name: Bioplus class: INDUSTRY name: Seoul National University Hospital name: Asan Medical Center name: Soonchunhyang University Hospital briefSummary: Purpose : This investigation intends to demonstrate that the investigational device, SkinPlus-HYAL Implant Lidocaine, is non-inferior to the comparator device, RESTYLANE Lidocaine, in terms of temporary wrinkle reduction effect, safety, and injection site pain when applied on nasolabial folds in adults.
\* In this investigation, the same subject receives both test and control treatments, one on each side of the nasolabial folds (matched pairs design). conditions: Nasal Disease conditions: Nasal Surgery studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Medical Device primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 100 type: ESTIMATED name: Investigational medical device (SkinPlus-HYAL Implant Lidocaine) name: Active Comparator: Active Comparator Medical Device (RESTYLANE Lidocaine) measure: Difference in the mean values of the Wrinkle Severity Rating Scale (WSRS) between the treatment and control groups as evaluated by an independent evaluator at 24 weeks after the application of the investigational medical device measure: Difference in the mean values of the WSRS between the treatment and control groups as evaluated by the investigator at 8, 16, 24, and 48 weeks after device application measure: Difference in the mean Global Aesthetic Improvement Scale (GAIS) values between the treatment and control groups as evaluated by the investigator at weeks 8, 16, 24, and 48 of the first post-device application phase compared to before application measure: Difference in the mean values of the WSRS between the treatment and control groups as evaluated by an independent evaluator at 48 weeks after device application. sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Seoul National University Hospital city: Seoul state: Jongnogu zip: 03080 country: Korea, Republic of lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06305507 id: 30923-N briefTitle: Differents Laser Applications on Plantar Fasciitis overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-06 date: 2024-07 date: 2024-03-12 date: 2024-03-13 name: University of Seville class: OTHER briefSummary: The objective of this randomized controlled clinical trial (RCT) with a double-blind technique and longitudinal chronology, entitled \"Effect of different laser applications on Plantar Fasciitis\", is to evaluate and compare the effectiveness of laser therapy low-level (LLLT) in local spot mode versus sweep mode in the reduction of pain associated with plantar fasciitis.
The investigators will compare the group undergoing local spot mode low-level laser therapy with the group undergoing sweeping mode low-level laser therapy to evaluate whether there are significant differences in pain reduction effects. conditions: Fasciitis, Plantar studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 62 type: ESTIMATED name: Focussed laser therapy name: Shower laser therapy measure: Pain Reduction in Patients with Plantar Fasciitis Treated with Laser Therapy (LLLT): Comparison between Local Spot Mode and Sweep Mode" measure: Fascia thickness sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Área Clínica de Podología city: Sevilla state: Andalucía zip: 41004 country: Spain lat: 37.38283 lon: -5.97317 facility: Facultad de Podologia city: Sevilla zip: 41009 country: Spain name: Aurora Castro, Prof titular role: CONTACT phone: 954486500 lat: 37.38283 lon: -5.97317 hasResults: False
nctId: NCT06305494 id: HE671008 briefTitle: Genitourinary Syndrome of Menopause in Thai Gynecologic Cancer Survivors overallStatus: RECRUITING date: 2024-03-14 date: 2024-12 date: 2024-12 date: 2024-03-12 date: 2024-04-25 name: Khon Kaen University class: OTHER briefSummary: Women often face common cancers like ovarian, uterine, and cervical cancers. Improvements in cancer detection and treatment mean more women survive. However, survivors can encounter challenges like ongoing pain, treatment complications, and fertility issues.
The main treatment for these symptoms is using vaginal estrogen, but it might not be suitable for some cancer survivors. Non-hormonal options like lubricants and moisturizers are alternatives. This study in Thailand aiming to explore how common these issues are among gynecological cancer survivors, their feelings about it, and how it affects their quality of life. conditions: Atrophic Vaginitis conditions: Gynecologic Cancer conditions: Lower Urinary Tract Symptoms studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 425 type: ESTIMATED measure: Prevalence of genitourinary syndrome of menopause measure: Severity of genitourinary syndrome of menopause measure: Quality of life of gynecologic cancer survivor measure: Attitude toward genitourinary syndrome of menopause in gynecologic cancer survivor sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Faculty of Medicine, Khon Kaen University status: RECRUITING city: Khon Kaen zip: 40002 country: Thailand name: Apiwat Jongjakapun, MD role: CONTACT email: apiwjo@kku.ac.th lat: 16.44671 lon: 102.833 hasResults: False
nctId: NCT06305481 id: OPT1099 briefTitle: Glaucoma Evaluation With the P200TE overallStatus: RECRUITING date: 2024-02-13 date: 2024-09-30 date: 2024-09-30 date: 2024-03-12 date: 2024-03-12 name: Optos, PLC class: INDUSTRY briefSummary: Images captured on the P200TE device on glaucoma patients conditions: Glaucoma studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 75 type: ESTIMATED name: P200TE measure: Number of images collected sex: ALL minimumAge: 22 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Werner Optometry status: RECRUITING city: Cajon state: California zip: 92019 country: United States name: Kristen Mendenhall role: CONTACT phone: 619-937-1056 email: kristen@wernerod.com lat: 34.29889 lon: -117.45644 facility: Specialty Eyecare Centre status: RECRUITING city: Bellevue state: Washington zip: 98004 country: United States name: Renee Cook role: CONTACT phone: 425-454-3937 email: rcook@specialtyeyecarecentre.com lat: 47.61038 lon: -122.20068 hasResults: False
nctId: NCT06305468 id: APHP240055 briefTitle: Prognosis of Disseminated and Cerebral Toxoplasmosis Hospitalized in Intensive Care in the Era of PCR Diagnosis acronym: TOXIC overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-04-01 date: 2026-04-01 date: 2024-03-12 date: 2024-03-12 name: Assistance Publique - Hôpitaux de Paris class: OTHER briefSummary: Toxoplasmosis is a common infection whose clinical severity can sometimes justify admission to intensive care, especially in immunocompromised patients.
This study should make it possible to evaluate the impact of different anti-infective treatment regimens and to highlight clinical-biological and prognostic differences depending on the type of underlying immunosuppression. conditions: Toxoplasmosis studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: RETROSPECTIVE count: 200 type: ESTIMATED measure: Mortality rate in intensive care. measure: Hospital mortality rate measure: Length of stay in intensive care measure: Duration of mechanical ventilation sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cochin hospital city: Paris zip: 75014 country: France lat: 48.85341 lon: 2.3488 hasResults: False
nctId: NCT06305455 id: HSD135 briefTitle: Resistance Profile of Escherichia Coli in Infections of Community Origin: The Importance of Antimicrobial Stewardship overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-07 date: 2024-10 date: 2024-03-12 date: 2024-03-12 name: José Raimundo Araujo de Azevedo class: OTHER briefSummary: The main objective of the study is to describe the antimicrobial resistance profile of E. coli isolated in patients from the community - defined as those with cultures collected within 48 hours of hospital admission - and admitted to the intensive care unit. conditions: Antimicrobial Resistance studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 200 type: ESTIMATED name: Escherichia coli ESBL measure: Prevalence of Escherichia coli resistance sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False